AnalystsPrakhar Agrawal
Prakhar Agrawal's Stock Forecasts

Analyst Ranking
Top 33%
#1601 out of 4929 analysts
Average Return
+1.26%
Win Rate
25%9 out of 36
Risk vs Reward
Poor
Good

Prakhar Agrawal's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Forma Therapeutics Holdings IncFMTX
+286.29%$5.18$20.01
2022-06-13 -
2022-10-13
Strong Buy
Moonlake ImmunotherapeuticsMLTX
+257.29%$17.63$62.99
2023-02-14 -
2024-02-13
Strong Buy
Moonlake ImmunotherapeuticsMLTX
+137.29%$21.32$50.59
2023-03-20 -
2024-03-19
Strong Buy
Dice Therapeutics IncDICE
+136.82%$19.61$46.44
2022-09-14 -
2023-06-20
Strong Buy
Moonlake ImmunotherapeuticsMLTX
+116.67%$22.20$48.10
2023-03-06 -
2024-03-05
Strong Buy

Prakhar Agrawal Analyst Color

Get additional color on Prakhar Agrawal's coverage of popular stocks

Prakhar Agrawal's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Structure Therapeutics IncGPCR
13Strong Buy$65.00+219.18%Reiterates
12 days ago
Trisalus Life Sciences IncTLSI
1Strong Buy$10.00+97.24%Initiates Coverage On
7 months ago
Moonlake ImmunotherapeuticsMLTX
8Strong Buy$78.00N/AReiterates
2 years ago
Akero Therapeutics IncAKRO
3Strong Buy$39.00N/AMaintains
2 years ago
Dice Therapeutics IncDICE
2Hold$48.00N/ADowngrades
2 years ago
Tg Therapeutics IncTGTX
2Strong Buy$24.00N/AReiterates
2 years ago
Spectrum Pharmaceuticals IncSPPI
1Hold$0.75N/AMaintains
2 years ago
Alaunos Therapeutics IncTCRT
1Strong Buy$450.00N/AAssumes
3 years ago
Forma Therapeutics Holdings IncFMTX
1Strong Buy$21.00N/AAssumes
3 years ago
Rapt Therapeutics IncRAPT
1Strong Buy$352.00N/AAssumes
3 years ago
Landos Biopharma IncLABP
1Strong Buy$390.00N/AInitiates Coverage On
4 years ago
Cymabay Therapeutics IncCBAY
1Strong Buy$8.00N/AInitiates Coverage On
4 years ago
Atyr Pharma IncATYR
1Strong Buy$15.00N/AInitiates Coverage On
4 years ago
Opus Genetics IncIRD
1Strong Buy$20.00N/AInitiates Coverage On
4 years ago
Equillium IncEQ
1Strong Buy$14.00N/AInitiates Coverage On
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.